Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
ALCOR Scientific Transforms ESR Testing: Extends Blood Sample Stability from 4 to 28 Hours
Diagnostic Company's iSED Analyzers Deliver Seven-Fold Stability Increase to Improve Accuracy, Efficiency,…
From Legacy to Innovation: Morphy Richards Refreshes at IFA 2025
BERLIN, Sept. 15, 2025 /PRNewswire/ -- At IFA 2025, futuristic technologies, robotics, and…
Demand AI Group Secures $2.5 Million in Funding from International Institutional and Local Investors
DENVER, Sept. 12, 2025 /PRNewswire/ -- Demand AI Group Inc. ("Demand AI"),…
Flipster Secures AAA Security Rating From CER.live, Placing Among Top 13 Most Secure Global Exchanges
PANAMA CITY, Sept. 11, 2025 /PRNewswire/ -- Flipster, a fast-growing crypto perpetuals…
XingImaging in partnership with SynuSight was awarded a grant from The Michael J. Fox Foundation to support development of the -synuclein PET tracer 18F-FD4 for Parkinson’s disease
NEW HAVEN, Conn., Sept. 10, 2025 /PRNewswire/ -- XingImaging in partnership with…
From Confusion to Clarity: How Fincover Is Cracking the Health Insurance Code for Indian Families in 2025
CHENNAI, India, Sept. 9, 2025 /PRNewswire/ -- In India, a single hospital…
UltiMaker Introduces Secure Line from the S series, Defense-Grade 3D Printing for High-Security, On-Demand Production
The Secure Line transforms additive manufacturing into a frontline tactical capability across…
NYSE Content Advisory: Pre-Market Update + S&P 500 enters week 0.8% from record
NEW YORK, Sept. 8, 2025 /PRNewswire/ -- The New York Stock Exchange…
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
September 07, 2025 18:25 ET | Source: Dianthus Therapeutics, Inc. NEW YORK…
